Book a Meeting

Anti-RGM A Antibody, Non-Fucosylated (BioBet-1568ZP) (CAT#: BioBet-1568ZP) Datasheet

Target
RGM A
Isotype
IgG
Description
ADCC-Enhanced anti-RGM A (h5F9.21) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Retinal Nerve Fiber Layer (RNFL) Degeneration
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced RGM A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
RGMA
Full Name
repulsive guidance molecule family member a
Background
This gene encodes a member of the repulsive guidance molecule family. The encoded protein is a glycosylphosphatidylinositol-anchored glycoprotein that functions as an axon guidance protein in the developing and adult central nervous system. This protein may also function as a tumor suppressor in some cancers. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]
Alternative Names
RGMA; repulsive guidance molecule family member a; RGM; repulsive guidance molecule A; RGM domain family, member A;
Gene ID
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with RGMA include Hemochromatosis Type 2 and Amusia.
Related Pathways
Its related pathways are Netrin-1 signaling and Signaling by BMP.
Function
Members of the Rejection Targeting Molecule (RGM) family, play multiple roles in the developmental and adult nervous system. Regulate the closure of the scalp neural tube, inhibit the growth of neurites, the branching of cortical neurons, and the formation of mature synapses. Binding to the receptor NEO1/neogenin can activate the RHOA-ROCK1/Rho-kinase signaling pathway through the unc5-arhgef12/LARG-PTK2/FAK1 cascade, leading to the breakdown of nerve growth cones and neurite growth inhibition. In addition, RGMA affects the HRAS-ptk2/FAK1-AKT1 pathway and binds to NEO1/neogenin to cause HRAS inactivation. It is also a co-receptor of bone morphogenetic protein (BMP) and may signal through SMAD1, SMAD5 and SMAD8.
Post-translational modifications
1.Autocatalytically cleaved at low pH; the two chains remain linked via two disulfide bonds 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn114, Asn159, and Asn389
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
h5F9.21
Host
Humanized
Species Reactivity
Human
Description
The RGMA binding proteins, particularly monoclonal antibody have the ability to bind to RGMA, and therefore neutralize the function of RGMA, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration.
Antibody Indication
Retinal Nerve Fiber Layer (RNFL) Degeneration

Retinal Nerve Fiber Layer (RNFL) Degeneration

Related Products

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas